Cargando…

Decline in serum progastrin-releasing peptide predicts the response of patients with small cell lung cancer to chemotherapy

The utility of serum progastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE) as biomarkers for treatment monitoring and as prognostic factors was investigated in small cell lung cancer (SCLC) patients. Patients were first diagnosed pathologically at the First Affiliated Hospital of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ming, Han, Dandan, Wang, Wei, Zhang, Yang, Li, Dan, Dai, Chunyang, Qian, Liting, Lin, Wenchu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577081/ https://www.ncbi.nlm.nih.gov/pubmed/33101495 http://dx.doi.org/10.3892/ol.2020.12164

Ejemplares similares

Instability of Plasma and Serum Progastrin-Releasing Peptide During Repeated Freezing and Thawing
por: Lee, Jae-Eun, et al.
Publicado: (2016)

Circulating progastrin-releasing peptide in the diagnosis of Small Cell Lung Cancer (SCLC) and in therapeutic monitoring
por: Barchiesi, Vittoria, et al.
Publicado: (2021)

Increased Progastrin-Releasing Peptide Expression is Associated with Progression in Gastric Cancer Patients
por: Li, Li, et al.
Publicado: (2020)

Diagnostic and therapeutic value of progastrin‐releasing peptide on small‐cell lung cancer: A Single‐Center Experience in China
por: Wu, Xiao‐Yuan, et al.
Publicado: (2018)

Association between Serum Progastrin Biomarker Level and Gastric Cancer
por: Amjadi, Omolbanin, et al.
Publicado: (2022)

Aptamer based surface plasma resonance assay for direct detection of neuron specific enolase and progastrin-releasing peptide (31-98)
por: Sun, Linlin, et al.
Publicado: (2021)

Clinical significance of progastrin-releasing peptide, neuron-specific enolase, chromogranin a, and squamous cell cancer antigen in pulmonary neuroendocrine tumors
por: TUTAR, Nuri, et al.
Publicado: (2019)

Targeting progastrin enhances radiosensitization of colorectal cancer cells
por: Kowalski-Chauvel, Aline, et al.
Publicado: (2017)

Acute effects of N‐terminal progastrin fragments on gastric acid secretion in man
por: Goetze, Jens P., et al.
Publicado: (2017)

Progastrin-Releasing Peptide Precursor and Neuron-Specific Enolase Predict the Efficacy of First-Line Treatment with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Among Non-Small-Cell Lung Cancer Patients Harboring EGFR Mutations
por: Dong, Juanjuan, et al.
Publicado: (2021)

Plasma progastrin‐releasing peptide level shows different predictive profiles for treatment response by androgen receptor axis‐targeted agents in patients with metastatic castration‐resistant prostate cancer
por: Yashi, Masahiro, et al.
Publicado: (2022)

Circulating miR-92b and miR-375 for monitoring the chemoresistance and prognosis of small cell lung cancer
por: Li, Ming, et al.
Publicado: (2020)

Progastrin Represses the Alternative Activation of Human Macrophages and Modulates Their Influence on Colon Cancer Epithelial Cells
por: Hernández, Carlos, et al.
Publicado: (2014)

The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients
por: You, Benoit, et al.
Publicado: (2019)

Prognostic Value of Plasma hPG(80) (Circulating Progastrin) in Metastatic Renal Cell Carcinoma
por: Kohli, Manish, et al.
Publicado: (2021)

Plasma hPG(80) (Circulating Progastrin) as a Novel Prognostic Biomarker for Hepatocellular Carcinoma
por: Dupuy, Marie, et al.
Publicado: (2022)

Association between post-operative hPG(80) (circulating progastrin) detectable level and worse prognosis in glioblastoma
por: Doucet, L., et al.
Publicado: (2023)

The G-protein coupled receptor 56, expressed in colonic stem and cancer cells, binds progastrin to promote proliferation and carcinogenesis
por: Jin, Guangchun, et al.
Publicado: (2017)

hPG(80) (circulating progastrin) as a blood biomarker for high-grade glial tumors: A pilot study
por: Casile, Melanie, et al.
Publicado: (2023)

FK228 sensitizes radioresistant small cell lung cancer cells to radiation
por: Li, Hong, et al.
Publicado: (2021)

Meta-Analysis of Serum Gastrin-Releasing Peptide Precursor as a Biomarker for Diagnosis of Small Cell Lung Cancer
por: Lv, Shui ping, et al.
Publicado: (2017)

Factors Associated with the Decision to Decline Chemotherapy in Metastatic Non-Small Cell Lung Cancer
por: Jabbal, Iktej Singh, et al.
Publicado: (2023)

Progastrin production transitions from Bmi1(+)/Prox1(+) to Lgr5(high) cells during early intestinal tumorigenesis
por: Giraud, J., et al.
Publicado: (2020)

Plasma hPG(80) (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort
por: Prieur, Alexandre, et al.
Publicado: (2023)

hPG(80) (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors
por: Chauhan, Aman, et al.
Publicado: (2022)

The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
por: Ma, Liying, et al.
Publicado: (2020)

Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
por: Ma, Liying, et al.
Publicado: (2021)

JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer
por: Wang, Huogang, et al.
Publicado: (2017)

Serum YKL-40 Level Is Associated with the Chemotherapy Response and Prognosis of Patients with Small Cell Lung Cancer
por: Xu, Chun-Hua, et al.
Publicado: (2014)

Comprehensive analysis of the expression, prognosis, and immune infiltrates for CHDs in human lung cancer
por: Lv, Yang, et al.
Publicado: (2022)

Exosomal miR-92b-3p Promotes Chemoresistance of Small Cell Lung Cancer Through the PTEN/AKT Pathway
por: Li, Ming, et al.
Publicado: (2021)

Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients
por: Zhang, Shiheng, et al.
Publicado: (2016)

Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling
por: Voortman, Johannes, et al.
Publicado: (2009)

Characteristics and outcomes of patients with advanced non-small-cell lung cancer who declined to participate in randomised clinical chemotherapy trials
por: Tanai, C, et al.
Publicado: (2009)

Serum Cystatin, Chemokine, and Gastrin-Releasing Peptide Precursors and Their Clinical Value in Patients with Chronic Renal Failure
por: Liu, Xiaoli, et al.
Publicado: (2022)

Combination treatment of RAD001 and BEZ235 exhibits synergistic antitumor activity via down-regulation of p-4E-BP1/Mcl-1 in small cell lung cancer
por: Hong, Bo, et al.
Publicado: (2017)

CircVAPA promotes small cell lung cancer progression by modulating the miR-377-3p and miR-494-3p/IGF1R/AKT axis
por: Hua, Jinghan, et al.
Publicado: (2022)

Overall Survival Analyses following Adjuvant Chemotherapy or Nonadjuvant Chemotherapy in Patients with Stage IB Non-Small-Cell Lung Cancer
por: Tu, Zegui, et al.
Publicado: (2021)

New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer
por: Nisman, Benjamin, et al.
Publicado: (2016)

Paclitaxel-loaded nanobubble targeted to pro-gastrin-releasing peptide inhibits the growth of small cell lung cancer
por: Wang, Jin-Ping, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gsv9fqbfsapecn4auuae3qkl0i